We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 3 of 29 for:    Recruiting, Not yet recruiting, Available Studies | "Shy-Drager Syndrome"

Oligomeric Alpha-synuclein in Multiple System Atrophy (BIOAMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01485549
Recruitment Status : Recruiting
First Posted : December 5, 2011
Last Update Posted : November 13, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF) and plasma levels.

Condition or disease
Multiple System Atrophy (MSA)

Detailed Description:

Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. No effective treatment is available. Together with PD and Lewy body dementia, MSA belongs to a group of neurodegenerative disorders, the alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein. The development of biological markers for the diagnosis and prognosis in MSA remains an unmet need. Such biological markers are crucial for future disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature in MSA. The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.

The study will compare alpha-synuclein levels in CSF and plasma between patients suffering from AMS and controls who are patients requiring spinal tap without being affected by a neurodegenerative disorder. The MSA patients and controls will receive CSF and blood sampling at one study visit.

Study Design

Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Oligomeric Alpha-synuclein Levels as a Biomarker for Multiple System Atrophy
Actual Study Start Date : November 26, 2012
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

MSA Patients
Patients suffering from Multiple system atrophy (MSA)
Patients requiring spinal tap without being affected by a neurodegenerative disorder.

Outcome Measures

Primary Outcome Measures :
  1. Concentration of oligomeric alpha-synuclein in cerebrospinal fluid (CSF). [ Time Frame: Day 0 ]

Secondary Outcome Measures :
  1. Total alpha-synuclein concentration in CSF and oligomeric/total alpha-synuclein ratio in CSF [ Time Frame: Day 0 ]
  2. Oligomeric and total alpha-synuclein concentration in plasma and oligomeric/total alpha-synuclein ratio in plasma [ Time Frame: Day 0 ]

Biospecimen Retention:   Samples With DNA
  • cerebrospinal fluid (CSF)
  • whole blood
  • plasma
  • blood serum
  • urine

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cases will be selected from cohort of 90 MSA patients referenced in Bordeaux University Hospital.

Controls will be selected from patients requiring spinal tap without being affected by a neurodegenerative disorder and paired in age and gender with cases.


Inclusion Criteria:

  • MSA patients :

    • Patients suffering from "probable" MSA according to clinical consensus criteria (Gilman et al, 2008)
    • Age ≥ 30
    • Written informed consent
    • Patient covered by the French health insurance system
  • Controls :

    • Patients not suffering from a neurodegenerative disorder and requiring a spinal tap
    • Age ≥ 30
    • Written informed consent
    • Patient covered by the French health insurance system

Exclusion Criteria:

  • MSA patients and controls :

    • UMSARS IV score > 4 points
    • Patient with coagulopathy, defined by an abnormal activated partial thromboplastin time or INR
    • Patient with thrombocytopenia
    • Patient under tutelage
    • Patient unable to give consent
    • Pregnant or breastfeeding women
    • Pathology leading to necrosis of the cerebral tissue
    • Significant anomaly of standard markers of Cerebrospinal fluid (CSF)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01485549

Contact: Wassilios MEISSNER, MD, PhD (0)557656420 ext +33 wassilios.meissner@chu-borfdeaux.fr
Contact: Olivier Flabeau, CCA olivier.flabeau@chu-bordeaux.fr

Bordeaux University Hospital Recruiting
Pessac, France, 33604
Contact: Wassilios MEISSNER, MD, PhD    (0)557656420 ext +33    wassilios.meissner@chu-bordeaux.fr   
Principal Investigator: Wassilios MEISSNER, MD, PhD         
Sub-Investigator: François TISON, MD, PhD         
Sub-Investigator: Anne-Cécile WIELANEK, MD         
Sub-Investigator: Olivier FLABEAU, MD         
Sponsors and Collaborators
University Hospital, Bordeaux
Principal Investigator: Wassilios MEISSNER, MD, PhD University Hospital, Bordeaux
Study Chair: Rodolphe THIEBAUT, MD, PhD USMR Bordeaux
More Information

Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT01485549     History of Changes
Other Study ID Numbers: CHUBX 2011/11
First Posted: December 5, 2011    Key Record Dates
Last Update Posted: November 13, 2017
Last Verified: November 2017

Keywords provided by University Hospital, Bordeaux:
Multiple system atrophy (MSA)
biological markers
cerebrospinal fluid

Additional relevant MeSH terms:
Multiple System Atrophy
Shy-Drager Syndrome
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Vascular Diseases
Cardiovascular Diseases